Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GCG | P01275 | 8/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397932 | 0.86 | GCG (0.48) | SMN1; SMN2GCG | |
| SCHEMBL718505 | 0.83 | NPC1 (0.42) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3402110 | 0.81 | CNR1 (0.39) | CNR2CNR1NPC1RAB9AKDM4E | |
| SCHEMBL718024 | 0.80 | GCG (0.43) | GCG | |
| SCHEMBL716868 | 0.77 | MEN1 (0.47) | KDM4ESMN1; SMN2GCGMAPT | |
| SCHEMBL3400480 | 0.75 | RCE1 (0.45) | GCG | |
| SCHEMBL720334 | 0.75 | RCE1 (0.59) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL720544 | 0.74 | GCG (0.46) | NPC1RAB9ASMN1; SMN2GCGALDH1A1 | |
| SCHEMBL3397384 | 0.73 | NPC1 (0.42) | NPC1RAB9AALDH1A1 | |
| SCHEMBL3395640 | 0.72 | GCG (0.51) | GCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | CNR2 1387/4885CNR1 1378/4885NPC1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.